Arvinas Inc (ARVN) — Quality & forensics
As of 2026-11-06 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 21
- Quality 25
- Growth 39
- Balance sheet 45
- Cash quality 35
- Capital allocation 75
- Momentum 10
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the distress zone (below 1.81). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — above the −1.78 threshold the literature flags for earnings-manipulation risk. A screen, not an accusation.
Continue: the ARVN chart & overview
FAQ · from the current data · as of 2026-11-06
Quick answers
What is Arvinas Inc's Closelooknet quality reading?
The composite reads 35/100 across 7 modules, as of 2026-11-06: valuation 21, quality 25, growth 39, balance sheet 45, cash quality 35, capital allocation 75, momentum 10. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Arvinas Inc's Altman Z-Score?
-1.47, which sits in the distress zone (below 1.81) as of 2026-11-06. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Arvinas Inc's Piotroski F-Score?
4 of 9, as of 2026-11-06. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Arvinas Inc's Beneish M-Score indicate?
-1.61 — above the −1.78 threshold the literature flags for earnings-manipulation risk, as of 2026-11-06. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- UCB.BR UCB SAindustry
- BION.SW BB Biotech AGindustry
- RIGL Rigel Pharmaceuticals Incindustry
- REPL Replimune Group Incindustry
- KOD Kodiak Sciences Incindustry
- XNCR Xencor Incindustry
- VCEL Vericel Corp Ordindustry
- MRNA Moderna Incindustry
- VRDN Viridian Therapeutics Incindustry
- ADMA ADMA Biologics Incindustry
- SEPN Septerna, Inc. Common Stockindustry
- PVLA Palvella Therapeutics, Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- LEGN Legend Biotech Corpindustry
- ORKA Oruka Therapeutics, Inc.industry
- MEDCL.PA Medincell SAindustry
- NEU.AU Neuren Pharmaceuticals Ltdindustry